SILVER SPRING, Md., Jan. 15, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing natural products and cell and gene therapy solutions for the treatment of human diseases, announced today its subsidiary, KnockOut Technologies, Ltd., has filed a patent in Thailand for all-natural product formulations and their potential use in preventing and treating infections caused by influenza viruses. The initial patent application was filed in January of 2008 and after a lengthy review process it was resubmitted to patent officials in Thailand by our counsel this week. The all-natural formulations described in the patent have the potential to impact upon outbreaks of influenza virus infections. Thailand was chosen for submission of this patent in 2008 as a result of endemic influenza in that region. "Seasonal" influenza (flu) is an acute viral infection that can affect all age groups, but children under two years of age, adults over 65, and those with weakened immune systems or with other serious illnesses such as diabetes, chronic heart, lung, and liver diseases, are at the highest risk. According to the World Health Organization (WHO), annual epidemics of seasonal flu result in about 3-5 million cases of severe illness and about 250,000-500,000 deaths worldwide. The natural patent formulations contain a mixture of orange oils. In standard laboratory tests used to determine antiviral activity, our formulations containing these ingredients were shown to be effective in killing these flu viruses. We believe acceptance of this patent represents an important step in the development of all-natural anti-viral formulations that will ultimately lead to approval by regulatory authorities for the sale of one or more products. Nuvilex has been planning to continue to expand its present work with groups in Thailand to aid in combating viruses particularly in Southeast Asia. The Company hopes to receive approval of the patent within 90-180 days.
About NuvilexNuvilex, Inc. (OTCQB:NVLX) has been a provider of all-natural products for many years and has expanded its company to become an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for research and medicine. In the biotechnology area of Nuvilex, our company's clinical offerings will include cancer, diabetes and other treatments using the company's cell and gene therapy expertise and live-cell encapsulation technology. The Nuvilex, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13494 Safe Harbor Statement This press release contains forward-looking statements described within the 1995 Private Securities Litigation Reform Act involving risks and uncertainties including product demand, market competition, and meeting current or future plans which may cause actual results, events, and performances, expressed or implied, to vary and/or differ from those contemplated or predicted. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or disclose unanticipated occurrences, except as required under applicable laws.
CONTACT: Investor Relations Contact: Marlin Molinaro Marmel Communications, LLC Ph: (702) 434-8692 email@example.com